Close

Look Who's "Pounding the Table" on One of Our Favorite Biotechs

It was the very first stock we recommended on the very first day we published Private Briefing back on Aug. 11, 2011.

We kept re-recommending the stock after that – and it kept going up in price.

The stock has surged as much as 663%.

And a respected stock researcher just rated this biotech as a “Buy.”

Let me tell you all about it…